A scoping review of the role of managed entry agreements in upcoming drugs for amyotrophic lateral sclerosis: learning from the case of spinal muscular atrophy
- 10 September 2024
- journal article
- research article
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 26 (1-2) , 48-57
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Sodium Phenylbutyrate and Tauroursodeoxycholic Acid: A Story of Hope Turned to Disappointment in Amyotrophic Lateral Sclerosis TreatmentClinical Drug Investigation, 2024
- Sodium Phenylbutyrate and Ursodoxicoltaurine: First ApprovalCNS Drugs, 2022
- Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and TisagenlecleucelPharmacoEconomics, 2021
- The economic burden of amyotrophic lateral sclerosis: a systematic reviewThe European Journal of Health Economics, 2021
- Costs of Illness of Spinal Muscular Atrophy: A Systematic ReviewApplied Health Economics and Health Policy, 2021
- A crisis in US drug pricing: Consequences for patients with neuromuscular diseases, physicians and society, part 1Muscle & Nerve, 2020
- The impact of managed entry agreements on pharmaceutical pricesHealth Economics, 2020
- Economic Studies in Motor Neurone Disease: A Systematic Methodological ReviewPharmacoEconomics, 2016
- The High Cost of Prescription Drugs in the United StatesJAMA, 2016
- Cross‐disease comparison of amyotrophic lateral sclerosis and spinal muscular atrophy reveals conservation of selective vulnerability but differential neuromuscular junction pathologyJournal of Comparative Neurology, 2015